Physician profile
William Stringer
NPI 1730156340
$12,843.97
in general payments reported to CMS, 2019-2025
48 companies · $2,320 in 2025
The $2,320 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $847 · 2021: $2,845 · 2022: $2,032 · 2023: $2,243 · 2024: $2,203 · 2025: $2,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,705 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,704.51 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,514.68 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,500.22 | 2020-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Pfizer INC. | $1,267.70 | 2019-2025 | |
| Lilly USA, LLC | $897.01 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $880.91 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $809.49 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $711.26 | 2019-2025 | Eliquis, Camzyos |
| Abbvie INC. | $472.95 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.49 | 2019-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $339.03 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $332.76 | 2021-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.35 | 2020-2025 | Jardiance |
| Abbott Laboratories | $297.75 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $293.83 | 2020-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $236.64 | 2020-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.